Study S003407

An Exploratory Clinical Study Evaluating Allogeneic iPSC-derived Pancreatic Islet Cells (CRG-002) for the Treatment of Diabetic Patients With Hypoglycemia Unawareness or Severe Hypoglycemic Events

ClinicalTrials.gov record

Registration

Registration: NCT07503028
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Masking: NONE
Status: ENROLLING_BY_INVITATION
Enrollment: 10
Start: 2025-10-17
Primary completion: 2028-01-18
Lead sponsor: Celregen Therapeutics
Conditions: T1DM - Type 1 Diabetes Mellitus; Pancreatogenic Diabetes Mellitus
Interventions: DRUG:CRG002
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Safety as assessed by number of adverse events accoridng to CTCAE v 6.0 [Within one year after CRG-002 transplantation]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.